Europe In Brief
This article was originally published in The Gray Sheet
Executive Summary
European clinical evaluation guidelines: The European Commission in December issued revised 1clinical evaluation guidelines explaining how manufacturers should conduct and document clinical evaluations of devices both before and after putting them on the market. "The clinical evaluation is expected to address the significance of any risks that remain after design risk mitigation strategies have been employed by the manufacturer," the guidelines state. The document notes that the extent of clinical evaluation needed depends on the nature, classification, intended use and risks of the particular device. For many devices embodying incremental modifications, it will be possible to draw on clinical experience with and literature reports on the safety and performance of equivalent devices, the guidelines note. For other devices - such as high risk devices, devices based on technologies where there is little or no experience, or those that represent a new clinical use - clinical investigations are likely to be required. The new guidelines, entitled MEDDEV 2.7.1 Rev. 3, take effect March 21 (2"The Gray Sheet" Aug. 17, 2009). They apply to medical devices generally and the device component of combination products; they do not cover in vitro diagnostics
You may also be interested in...
Cert Of Conformity Questions Remain From EU Devices Directive Revisions
It is unclear whether companies will need to revise their existing certificates of conformity in order to comply with upcoming revisions to the Medical Device Directives in Europe, according to Hogan & Hartson attorney Elisabethann Wright
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.